# Serplulimab Combined With CCRT for LS-SCLC.

> **NCT06295926** · PHASE2 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 96 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Serplulimab

## Key facts

- **NCT ID:** NCT06295926
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-04
- **Primary completion:** 2027-01-25
- **Final completion:** 2027-12-31
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2024-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06295926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06295926, "Serplulimab Combined With CCRT for LS-SCLC.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06295926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*